A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Trial ID: NCT02864888

Interventional - Phase 3 - Not yet recruiting

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

Conditions

• Brain Stem Glioma

Interventions

• Radiation
• Atengenal
• Astugenal

Eligibility

Inclusion criteria

• Enrolled in BRI-BT-52

Exclusion criteria

• Not enrolled in BRI-BT-52

Sponsor

Burzynski Research Institute

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows